Description
This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.
Faculty
- Aleksander Krag (Moderator)
- Naim Alkhouri (Faculty)
- Sven Francque (Faculty)
- Amalia Gastaldelli (Faculty)
Related episodes
- Season 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
- EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
- Season 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease Awareness
- Season 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizon
ℹ️ Please click here to access the podcast version of this EASL Studio episode.